Comprehensive Document about the Handling of OOE and OOT Results
Recommendation

Thursday, 3 September 2026 9 .00 - 17.00 h
Establishment, Use and Maintenance of Analytical Reference Substances
How are OOE and OOT results in the pharmaceutical industry to be recorded and assessed nowadays? To answer this question, the ECA Quality Control Working Group and representatives from authorities and industry compiled a guidance document about the handling of Out-of-Expectation (OOE) and Out-of-Trend (OOT) results.
This 70 page document covers the following issues:
- Regulatory references
- Overview of data management in the laboratory and the analytical process
- Responsibilities for QC and QA
- Purpose of trend analysis
- The concept of control charts
- Detection and handling of OOE results
- Statistical process control (SPC) of continuous and discrete data
- Techniques for the retrospective review of historical data
- Trend analysis in stability testing
This document also includes seven Annexes; a technical glossary and worked examples to visualize the most important statistical tools and regression methods for a proper setting of stability trend limits.
Related GMP News
08.07.2026Revised Annex 19 on Reference and Retention Samples
01.07.2026Several FDA Warning Letters and Untitled Letters on Asbestos Testing of Talc in OTC Drug Products
24.06.2026Analytical Quality Group Developments January through April 2026
17.06.2026BioPhorum Publishes a Roadmap for QC Sample Test Execution
03.06.2026EMA Provides an Outlook on the Product-Specific Bioequivalence Guidelines Expected in 2026
03.06.2026FDA Warning Letter: Missing Method Validation - From a QC Topic to a Market-Access Problem


